B

Brainstorm Cell Therapeutics
D

BCLI

1.24000
USD
0.00
(0.00%)
Market Closed
Volume
193
EPS
-3
Div Yield
-
P/E
-0
Market Cap
7,072,248
OverviewSignalsIdeasNews
Related Instruments
    A
    APLS
    -1.750
    (-6.24%)
    26.280 USD
    A
    ASND
    2.160
    (1.74%)
    126.510 USD
    A
    ATHA
    -0.03290
    (-4.63%)
    0.67800 USD
    M
    MBIO
    -0.01120
    (-4.76%)
    0.22400 USD
    M
    MDB
    -11.99
    (-4.11%)
    279.79 USD
    Q
    QURE
    -0.55000
    (-8.14%)
    6.21000 USD
    R
    RYTM
    -3.540
    (-5.93%)
    56.190 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    More
News

Title: Brainstorm Cell Therapeutics

Sector: Healthcare
Industry: Biotechnology
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.